NCT04492254View on ClinicalTrials.gov

Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions
COVID-19
Interventions
DRUG

Enoxaparin

The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.

Trial Locations (3)

Unknown

Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne

Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat

Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
lead

Thrombosis Research Institute

OTHER

collaborator

Sanofi

INDUSTRY

NCT04492254 - Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients | Biotech Hunter | Biotech Hunter